ABSOLUTE BENEFIT OF LENVATINIB PLUS ANTI-PD-1 FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA FROM A REAL WORLD STUDY

被引：0
|
作者：
Chang, Xiujuan [1 ]
Yu, Shumin [1 ,2 ]
Pang, Jianzhi [1 ]
Zhang, Wei [1 ]
Kong, Huifang [1 ]
Huang, Jiagan [1 ]
Zhang, Guojie [1 ]
Zhang, Huixin [1 ]
Gu, Yueyue [1 ,3 ]
Dong, Zheng [1 ]
Chen, Yan [1 ]
Yang, Bin [1 ]
Liu, Jingping [4 ]
Yang, Yongping [1 ]
Zeng, Zhen [1 ,2 ,3 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[2] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China
[3] Anhui Med Univ, Sch Clin Med 5, Hefei, Anhui, Peoples R China
[4] Elect Power Hosp Beijing, Beijing, Peoples R China
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4402
引用
下载
收藏
页码：S1305 / S1306
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of donafenib combined with anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma (HCC): A retrospective real-world study.
    Liu, Sulai
    Zhou, Shuyi
    Song, Yinghui
    Liu, Jianming
    Guo, Chao
    Yang, Pingzhou
    Li, Ou
    Yi, Weimin
    Peng, Chuang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
    Chiang, Hsueh-Chien
    Lee, Yang-Cheng
    Chang, Ting-Tsung
    Lin, Yih-Jyh
    Wu, Hung-Tsung
    Wang, Chung-Teng
    Chen, Chiung-Yu
    Chen, Po-Jun
    Hsieh, Ming-Tsung
    Lin, Sheng-Hsiang
    Chen, Shang-Hung
    Chuang, Chiao-Hsiung
    Wu, I-Chin
    Hong, Tzu-Chun
    Wu, Juei-Seng
    Han, Meng-Zhi
    Chen, Wei-Ting
    Chiang, Chien-Ming
    Hung, Kuan-Kai
    Kuo, Hsin-Yu
    CANCERS, 2023, 15 (03)
  • [33] The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study
    Wang, Xishu
    Sun, Ximin
    Lei, Yongrong
    Fang, Lingyan
    Wang, Yuedi
    Feng, Kai
    Xia, Feng
    BMC CANCER, 2024, 24 (01)
  • [34] Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
    Zhao, Shu
    Zhou, Minhang
    Wang, Peng
    Yang, Jing
    Zhang, Dong
    Yin, Fan
    Song, Peng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [35] Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
    Renguo Guan
    Jie Mei
    Shaohua Li
    Wenping Lin
    Min Deng
    Wei Wei
    Rongping Guo
    Hepatology International, 2023, 17 : 765 - 769
  • [36] Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
    Guan, Renguo
    Mei, Jie
    Li, Shaohua
    Lin, Wenping
    Deng, Min
    Wei, Wei
    Guo, Rongping
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 765 - 769
  • [37] A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma
    Finn, Richard
    Ikeda, Masafumi
    Zhu, Andrew
    Sung, Max W.
    Baron, Ari D.
    Kudo, Masatoshi
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Shuichi
    Pracht, Marc
    Mamontov, Konstantin
    Meyer, Tim
    Mody, Kalgi
    Kubota, Tomoki
    Dutcus, Corina E.
    Saito, Kenichi
    Siegel, Abby B.
    Dubrovsky, Leonid
    Llovet, Josep M.
    JOURNAL OF HEPATOLOGY, 2020, 73 : S120 - S121
  • [38] Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
    Zhang, Wenwen
    Tong, Shuang
    Hu, Bingyang
    Wan, Tao
    Tang, Haowen
    Zhao, Feilong
    Jiao, Tianyu
    Li, Junfeng
    Zhang, Ze
    Cai, Jinping
    Ye, Huiyi
    Wang, Zhanbo
    Chen, Shiqing
    Wang, Yafei
    Li, Xuerui
    Wang, Fangzhou
    Cao, Junning
    Tian, Lantian
    Zhao, Xiaochen
    Chen, Mingyi
    Wang, Hongguang
    Cai, Shouwang
    Hu, Minggen
    Bai, Yuezong
    Lu, Shichun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [39] Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
    Jia, Meng
    Jia, Jiang-Kun
    Xu, Jian
    Xue, Huan-Zhou
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2625 - 2638
  • [40] Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study
    Xu, Bin
    Dong, Sanyuan
    Bai, Xue-Li
    Song, Tian-Qiang
    Zhang, Bo-Heng
    Zhou, Le-Du
    Chen, Yong-Jun
    Zeng, Zhi-Ming
    Wang, Kui
    Zhao, Hai-Tao
    Lu, Na
    Zhang, Wei
    Li, Xu-Bin
    Zheng, Su-Su
    Long, Guo
    Yang, Yu-Chen
    Huang, Hua-Sheng
    Huang, Lan-Qing
    Wang, Yun-Chao
    Liang, Fei
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Zhou, Jian
    Zeng, Meng-Su
    Fan, Jia
    Rao, Sheng-Xiang
    Sun, Hui-Chuan
    LIVER CANCER, 2023, 12 (03) : 262 - 276
12345